دورية أكاديمية
أعرض في EDS

The development of type 2 diabetes management in people with severe mental illness in the Capital Region of Denmark from 2001 to 2015.

التفاصيل البيبلوغرافية
العنوان: The development of type 2 diabetes management in people with severe mental illness in the Capital Region of Denmark from 2001 to 2015.
المؤلفون: Bakkedal C; The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Persson F; Complications Research, Steno Diabetes Center Copenhagen, Herlev, Denmark., Christensen MB; Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.; Copenhagen Center for Translational Research, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark., Kriegbaum M; The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Mohr GH; Center for Neuropsychiatric Schizophrenia Research, CNSR, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark., Andersen JS; The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Lind BS; Department of Clinical Biochemistry, Copenhagen University Hospital, Hvidovre, Denmark., Lykkegaard C; The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.; Department of Hematology, University Hospital Copenhagen, Rigshospitalet, Denmark., Siersma V; The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Rozing MP; The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.; Department O Rigshospitalet, Psychiatric Center of Copenhagen, Copenhagen, Denmark.
المصدر: Acta psychiatrica Scandinavica [Acta Psychiatr Scand] 2024 Mar; Vol. 149 (3), pp. 219-233. Date of Electronic Publication: 2024 Jan 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 0370364 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0447 (Electronic) Linking ISSN: 0001690X NLM ISO Abbreviation: Acta Psychiatr Scand Subsets: MEDLINE
أسماء مطبوعة: Publication: Malden, MA : Wiley-Blackwell
Original Publication: Copenhagen : Munksgaard International Publishers
مواضيع طبية MeSH: Diabetes Mellitus, Type 2* , Mental Disorders*/epidemiology , Cardiovascular Diseases*/epidemiology, Humans ; Cohort Studies ; Angiotensin Receptor Antagonists ; Glycated Hemoglobin ; Angiotensin-Converting Enzyme Inhibitors ; Denmark ; Glucose
مستخلص: Background: Type 2 diabetes (T2D) treatment has changed markedly within the last decades. We aimed to explore whether people with severe mental illness (SMI) have followed the same changes in T2D treatment as those without SMI, as multiple studies suggest that people with SMI receive suboptimal care for somatic disorders.
Methods: In this registry-based annual cohort study, we explored the T2D treatment from 2001 to 2015 provided in general practices of the Greater Copenhagen area. We stratified the T2D cohorts by their pre-existing SMI status. T2D was defined based on elevated glycated hemoglobin (≥48 mmol/mol) or glucose (≥11 mmol/L) using data from the Copenhagen Primary Care Laboratory Database. Individuals with schizophrenia spectrum disorders (ICD-10 F20-29) or affective disorders (bipolar disorder or unipolar depression, ICD-10 F30-33) were identified based on hospital-acquired diagnoses made within 5 years before January 1 each year for people with prevalent T2D or 5 years before meeting our T2D definition for incident patients. For comparison, we defined a non-SMI group, including people who did not have a hospital-acquired diagnosis of schizophrenia spectrum disorders, affective disorders, or personality disorders. For each calendar year, we assembled cohorts of people with T2D with or without SMI. We used Poisson regression to calculate the rates per 100 person-years of having at least one biochemical test (glycated hemoglobin, low-density lipoprotein cholesterol, estimated glomerular filtration rate, and urine albumin-creatinine ratio), having poor control of these biochemical results, taking glucose-lowering or cardiovascular medications, or experiencing a clinical outcome, including all-cause mortality and cardiovascular mortality. Three outcomes (cardiovascular events, cardiovascular mortality, and all-cause mortality) were additionally examined and adjusted for age and sex in a post hoc analysis.
Results: From 2001 to 2015, 66,914 individuals were identified as having T2D. In 2015, 1.5% of the study population had schizophrenia spectrum disorder and 1.4% had an affective disorder. The number of people who used biochemical tests or had poor biochemical risk factor control was essentially unrelated to SMI status. One exception was that fewer LDL cholesterol tests were done on people with affective disorders and schizophrenia spectrum disorders at the beginning of the study period compared to people in the non-SMI group. This difference gradually diminished and was almost nonexistent by 2011. There was also a slightly slower rise in UACR test rates in the SMI groups compared to other people with T2D during the period. Throughout the study period, all groups changed their use of medications in similar ways: more metformin, less sulfonylurea, more lipid-lowering drugs, and more ACEi/ARBs. However, people with schizophrenia disorder consistently used fewer cardiovascular medications. Cardiovascular events were more common in the affective disorder group compared to the non-SMI group from 2009 to 2015 (rate ratio 2015 : 1.36 [95% CI 1.18-1.57]). After adjustment for age and sex, all-cause mortality was significantly higher among people with a schizophrenia spectrum disorder each year from 2003 to 2015 compared to the non-SMI group (rate ratio 2015 : 1.99 [95% CI 1.26-3.12]).
Conclusion: Persons with schizophrenia or affective disorders demonstrated the same treatment changes for T2D as those without SMI in general practice. The lower use of most types of cardiovascular medications among people with schizophrenia disorders indicates potential undertreatment of hypertension and dyslipidemia and remains throughout the study period. Cardiovascular events were most common among people with affective disorders, but this was not reflected in a higher proportion using cardiovascular preventive medications. This knowledge should be considered in the management of this vulnerable patient group.
(© 2024 The Authors. Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd.)
References: Laursen TM, Wahlbeck K, Hallgren J, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PloS One. 2013;8(6):e67133.
Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res. 2011;131(1-3):101-104.
De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412-424.
Hert MDE, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52-77.
Ward M, Druss B. The epidemiology of diabetes in psychotic disorders. Lancet Psychiatry. 2015;2(5):431-451.
Holt RI, Mitchell AJ. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol. 2015;11(2):79-89.
Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol. 2021;18(2):136-145.
Kugathasan P, Horsdal HT, Aagaard J, Jensen SE, Laursen TM, Nielsen RE. Association of Secondary Preventive Cardiovascular Treatment after Myocardial Infarction with Mortality among Patients with Schizophrenia. JAMA Psychiatry. 2018;75(12):1234-1240.
Nielsen RE, Kugathasan P, Straszek S, Jensen SE, Licht RW. Why are somatic diseases in bipolar disorder insufficiently treated? Int J Bipolar Disord. 2019;7(1):12.
Knudsen L, Scheuer SH, Diaz LJ, et al. Indicators of quality of diabetes care in persons with type 2 diabetes with and without severe mental illness: a Danish nationwide register-based cohort study. Lancet reg Health Eur. 2023;26:100565.
Behandlingsrådet. Behandlingsrådets report vedrørende ulighed i somatisk behandling af patienter med psykiske lidelser. https://behandlingsraadet.dk/ulighed-i-sundhed/analyse-2022-2023/analyse-2022.
Jorgensen ME, Kristensen JK, Reventlov Husted G, Cerqueira C, Rossing P. The Danish adult Diabetes registry. Clin Epidemiol. 2016;8:429-434.
Pottegard A, Andersen JH, Sondergaard J, Thomsen RW, Vilsboll T. Changes in the use of glucose-lowering drugs: a Danish nationwide study. Diabetes Obes Metab. 2023;25(4):1002-1010.
Jorgensen M, Mainz J, Carinci F, Thomsen RW, Johnsen SP. Quality and predictors of Diabetes care among patients with schizophrenia: a Danish Nationwide study. Psychiatr Serv. 2018;69(2):179-185.
Knudsen L, Hansen DL, Joensen LE, et al. Need for improved diabetes support among people with psychiatric disorders and diabetes treated in psychiatric outpatient clinics: results from a Danish cross-sectional study. BMJ Open Diabetes Res Care. 2022;10(1):e002366.
Scheuer SH, Kosjerina V, Lindekilde N, et al. Severe mental illness and the risk of Diabetes complications: a Nationwide, register-based cohort study. J Clin Endocrinol Metab. 2022;107(8):e3504-e3514.
Scheuer SH, Fleetwood KJ, Licence KAM, et al. Severe mental illness and quality of care for type 2 diabetes: a retrospective population-based cohort study. Diabetes Res Clin Pract. 2022;190:110026.
Rohde C, Knudsen JS, Schmitz N, Ostergaard SD, Thomsen RW. The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA(1c)/LDL target achievement in newly diagnosed type 2 diabetes. Diabetologia. 2021;64(2):361-374.
Ribe AR, Laursen TM, Sandbaek A, Charles M, Nordentoft M, Vestergaard M. Long-term mortality of persons with severe mental illness and diabetes: a population-based cohort study in Denmark. Psychol Med. 2014;44(14):3097-3107.
Kreyenbuhl J, Dickerson FB, Medoff DR, et al. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. J Nerv Ment Dis. 2006;194(6):404-410.
Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1):15-22.
Bruins J, Pijnenborg GHM, van den Heuvel ER, et al. Persistent low rates of treatment of metabolic risk factors in people with psychotic disorders: a PHAMOUS study. J Clin Psychiatry. 2017;78(8):1117-1125.
Weiss AP, Henderson DC, Weilburg JB, et al. Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatr Serv. 2006;57(8):1145-1152.
Ferrannini G, Norhammar A, Gyberg V, Mellbin L, Rydén L. Is coronary artery disease inevitable in type 2 Diabetes? From a Glucocentric to a holistic view on patient management. Diabetes Care. 2020;43(9):2001-2009.
Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the steno type 2 randomised study. Lancet. 1999;353(9153):617-622.
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393.
DSAM. Type 2-diabetes i almen praksis. En Evidensbaseret vejledning. 2004.
DSAM. Type 2 diabetes - et metabolisk syndrom. 2012.
Health DP. CopLab - The Copenhagen Primary Care Laboratory Database.
Schmidt M, Pedersen L, Sorensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-549.
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490.
Mors O, Perto GP, Mortensen PB. The Danish Psychiatric central research register. Scand J Public Health. 2011;39(7 Suppl):54-57.
Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46(3):dyw213.
Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39(7 Suppl):26-29.
Heinrich NS, Kriegbaum M, Grand MK, Lind BS, Andersen CL, Persson F. Biochemical profiling, pharmacological management and clinical outcomes in type 2 diabetes in Danish primary care from 2001 to 2015. Prim Care Diabetes. 2022;16(6):818-823.
American Diabetes A, American Psychiatric A. American Association of Clinical E, north American Association for the Study of O. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
Seidu S, Than T, Kar D, et al. Therapeutic inertia amongst general practitioners with interest in diabetes. Prim Care Diabetes. 2018;12(1):87-91.
Bakkedal C, Persson F, Kriegbaum M, et al. Diabetes treatment for persons with severe mental illness: a registry-based cohort study to explore medication treatment differences for persons with type 2 diabetes with and without severe mental illness. PloS One. 2023;18(6):e0287017.
Kristensen FP, Rohde C, Ostergaard SD, Thomsen RW. Four-year HbA1c and LDL-cholesterol trajectories among individuals with mental disorders and newly developed type 2 diabetes. Brain Behav. 2021;11(11):e2372.
Nieuwenhuijse EA, Struijs JN, Sutch SP, Numans ME, Vos RC. Achieving diabetes treatment targets in people with registered mental illness is similar or improved compared with those without: analyses of linked observational datasets. Diabet Med. 2022;39(6):e14835.
Knudsen ST, Bodegard J, Birkeland KI, et al. Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015. Prim Care Diabetes. 2021;15(2):262-268.
Pendlebury J, Holt R. Managing diabetes in people with severe mental illness. J Diabetes Nurs. 2010;14:328-339.
Rohde C, Nielsen JS, Schollhammer Knudsen J, Thomsen RW, Ostergaard SD. Risk factors associated with mortality among individuals with type 2 diabetes and depression across two cohorts. Eur J Endocrinol. 2022;187(4):567-577.
Laursen TM, Mortensen PB, MacCabe JH, Cohen D, Gasse C. Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study. Psychol Med. 2014;44(8):1625-1637.
RØNn PF, Carstensen B, Knudsen JS, Persson F, JØRgensen ME. 1467-P: National Trends in the Use of Lipid-Lowering Drugs among Type 2 Diabetes Patients in Denmark from 1997 to 2017. Diabetes. 2019;68(Supplement_1).
Dominguez H, Schramm TK, Norgaard ML, et al. Initiation and persistence to statin treatment in patients with Diabetes receiving glucose-lowering medications 1997- 2006. Open Cardiovasc Med J. 2009;3:152-159.
Kreyenbuhl J, Medoff DR, Seliger SL, Dixon LB. Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and type 2 diabetes. Schizophr Res. 2008;101(1-3):256-265.
Toender A, Vestergaard M, Munk-Olsen T, Larsen JT, Kristensen JK, Laursen TM. Risk of diabetic complications and subsequent mortality among individuals with schizophrenia and diabetes - a population-based register study. Schizophr Res. 2020;218:99-106.
De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10(2):138-151.
معلومات مُعتمدة: Novo Nordisk Fonden; Bispebjerg Hospital; Copenhagen Center for Health Technology
فهرسة مساهمة: Keywords: affective disorders; schizophrenia disorders; severe mental illness; treatment quality; type 2 diabetes
المشرفين على المادة: 0 (Angiotensin Receptor Antagonists)
0 (Glycated Hemoglobin)
0 (Angiotensin-Converting Enzyme Inhibitors)
IY9XDZ35W2 (Glucose)
تواريخ الأحداث: Date Created: 20240106 Date Completed: 20240208 Latest Revision: 20240624
رمز التحديث: 20240624
DOI: 10.1111/acps.13650
PMID: 38183340
قاعدة البيانات: MEDLINE
الوصف
تدمد:1600-0447
DOI:10.1111/acps.13650